Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 May 22;106(11):1798-806.
doi: 10.1038/bjc.2012.167. Epub 2012 Apr 26.

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

H R Ali  1 , S-J Dawson, F M Blows, E Provenzano, P D Pharoah, C Caldas
Affiliations
Comparative Study

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

H R Ali et al. Br J Cancer. .

Abstract

Background: Proliferation has emerged as a major prognostic factor in luminal breast cancer. The immunohistochemical (IHC) proliferation marker Ki67 has been most extensively investigated but has not gained widespread clinical acceptance.

Methods: We have conducted a head-to-head comparison of a panel of proliferation markers, including Ki67. Our aim was to establish the marker of the greatest prognostic utility. Tumour samples from 3093 women with breast cancer were constructed as tissue microarrays. We used IHC to detect expression of mini-chromosome maintenance protein 2, Ki67, aurora kinase A (AURKA), polo-like kinase 1, geminin and phospho-histone H3. We used a Cox proportional-hazards model to investigate the association with 10-year breast cancer-specific survival (BCSS). Missing values were resolved using multiple imputation.

Results: The prognostic significance of proliferation was limited to oestrogen receptor (ER)-positive breast cancer. Aurora kinase A emerged as the marker of the greatest prognostic significance in a multivariate model adjusted for the standard clinical and molecular covariates (hazard ratio 1.3; 95% confidence interval 1.1-1.5; P=0.005), outperforming all other markers including Ki67.

Conclusion: Aurora kinase A outperforms other proliferation markers as an independent predictor of BCSS in ER-positive breast cancer. It has the potential for use in routine clinical practice.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Photomicrographs of representative immunostaining for all the proliferation markers.
Figure 2
Figure 2
Kaplan–Meier survival plot of AURKA scores in ER+ disease. AURKA expression as Allred proportion scores (0–4, because there were no ER+ cases with a score of 5) (Log-rank <0.0001).
Figure 3
Figure 3
Bar charts illustrating the relationship between AURKA and (A) grade (B) and molecular subtype in ER-positive disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, Green AR, Reis-Filho JS, Ellis IO (2010) Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol 222(4): 388–399 - PubMed
    1. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR (2011) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 127(3): 591–599 - PubMed
    1. Ali AM, Dawson SJ, Blows FM, Provenzano E, Ellis IO, Baglietto L, Huntsman D, Caldas C, Pharoah PD (2011) Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer 104(4): 693–699 - PMC - PubMed
    1. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C (2012) A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 226(1): 97–107 - PubMed
    1. Azzato E, Greenberg D, Shah M, Blows F, Driver K, Caporaso N, Pharoah P (2009) Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 100(11): 1806–1811 - PMC - PubMed

Publication types

MeSH terms